{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:54:45Z","timestamp":1791507285159,"version":"4.3.4"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"DOI":"10.1186\/s13195-026-02065-w","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T02:35:03Z","timestamp":1776998103000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effects of the novel phosphodiesterase 9 inhibitor irsenontrine on CSF proteomics profile in A\u03b2+\u2009and A\u03b2- dementia with Lewy bodies patients"],"prefix":"10.1186","volume":"18","author":[{"given":"Marlies","family":"Oosthoek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sjors G.J.G.","family":"In \u2019t Veld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Vermunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanqing","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"van Ingen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marleen","family":"Koel-Simmelink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Everard G.B.","family":"Vijverberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satya","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Hersch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Irizarry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallavi","family":"Sachdev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte E.","family":"Teunissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"2065_CR1","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1007\/s40520-020-01774-y","volume":"33","author":"P Soysal","year":"2021","unstructured":"Soysal P, Tan SG. The prevalence and co-incidence of geriatric syndromes in older patients with early-stage Alzheimer\u2019s disease and dementia with Lewy bodies. Aging Clin Exp Res. 2021;33:2599\u2013603. https:\/\/doi.org\/10.1007\/s40520-020-01774-y.","journal-title":"Aging Clin Exp Res"},{"key":"2065_CR2","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00401-020-02255-2","volume":"141","author":"J Attems","year":"2021","unstructured":"Attems J, et al. Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study. Acta Neuropathol. 2021;141:159\u201372. https:\/\/doi.org\/10.1007\/s00401-020-02255-2.","journal-title":"Acta Neuropathol"},{"key":"2065_CR3","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/wnl.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith IG, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017;89:88\u2013100. https:\/\/doi.org\/10.1212\/wnl.0000000000004058.","journal-title":"Neurology"},{"key":"2065_CR4","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s40263-021-00883-0","volume":"36","author":"L Azhar","year":"2022","unstructured":"Azhar L, Kusumo RW, Marotta G, Lanct\u00f4t KL, Herrmann N. Pharmacological Management of Apathy in Dementia. CNS Drugs. 2022;36:143\u201365. https:\/\/doi.org\/10.1007\/s40263-021-00883-0.","journal-title":"CNS Drugs"},{"key":"2065_CR5","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s40266-018-00636-7","volume":"36","author":"LA Hershey","year":"2019","unstructured":"Hershey LA, Coleman-Jackson R. Pharmacological Management of Dementia with Lewy Bodies. Drugs Aging. 2019;36:309\u201319. https:\/\/doi.org\/10.1007\/s40266-018-00636-7.","journal-title":"Drugs Aging"},{"key":"2065_CR6","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.jalz.2017.06.1856","volume":"13","author":"M Ando","year":"2017","unstructured":"Ando M, Kotani S, Watanabe N, Fukushima T. [P3\u2013043]: PRECLINICAL CHARACTERIZATION OF E2027, A NOVEL PHOSPHODIESTERASE 9 INHIBITOR. Alzheimer\u2019s Dement. 2017;13:946\u2013P946. https:\/\/doi.org\/10.1016\/j.jalz.2017.06.1856.","journal-title":"Alzheimer\u2019s Dement"},{"key":"2065_CR7","doi-asserted-by":"publisher","unstructured":"Ando M, P3-062: Effect of repeated administration of e, a novel Phosphodiesterase-9 inhibitor, on cyclic GMP levels in rat cerebrospinal fluid. 2027,. Alzheimer\u2019s & Dementia 14, P1088\u2013P1088 (2018). https:\/\/doi.org\/10.1016\/j.jalz.2018.06.1418","DOI":"10.1016\/j.jalz.2018.06.1418"},{"key":"2065_CR8","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1124\/pr.110.002907","volume":"62","author":"SH Francis","year":"2010","unstructured":"Francis SH, Busch JL, Corbin JD. cGMP-Dependent Protein Kinases and cGMP Phosphodiesterases in Nitric Oxide and cGMP Action. Pharmacol Rev. 2010;62:525\u201363. https:\/\/doi.org\/10.1124\/pr.110.002907.","journal-title":"Pharmacol Rev"},{"key":"2065_CR9","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.freeradbiomed.2022.11.022","volume":"193","author":"MR Tropea","year":"2022","unstructured":"Tropea MR, et al. Nitric oxide\/cGMP\/CREB pathway and amyloid-beta crosstalk: From physiology to Alzheimer\u2019s disease. Free Radic Biol Med. 2022;193:657\u201368. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2022.11.022.","journal-title":"Free Radic Biol Med"},{"key":"2065_CR10","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1038\/npp.2014.106","volume":"39","author":"E Bollen","year":"2014","unstructured":"Bollen E, et al. Improved Long-Term Memory via Enhancing cGMP-PKG Signaling Requires cAMP-PKA Signaling. Neuropsychopharmacology. 2014;39:2497\u2013505. https:\/\/doi.org\/10.1038\/npp.2014.106.","journal-title":"Neuropsychopharmacology"},{"key":"2065_CR11","doi-asserted-by":"publisher","first-page":"110428","DOI":"10.1016\/j.neuropharm.2025.110428","volume":"273","author":"Y Ishihara","year":"2025","unstructured":"Ishihara Y, et al. A novel selective phosphodiesterase 9 inhibitor, irsenontrine (E2027), enhances GluA1 phosphorylation in neurons and improves learning and memory via cyclic GMP elevation. Neuropharmacology. 2025;273:110428. https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110428.","journal-title":"Neuropharmacology"},{"key":"2065_CR12","doi-asserted-by":"publisher","first-page":"178126","DOI":"10.1016\/j.ejphar.2025.178126","volume":"1006","author":"M Ando","year":"2025","unstructured":"Ando M, et al. E2027 (irsenontrine), a phosphodiesterase 9 inhibitor, enhances cholinergic function when combined with donepezil hydrochloride. Eur J Pharmacol. 2025;1006:178126. https:\/\/doi.org\/10.1016\/j.ejphar.2025.178126.","journal-title":"Eur J Pharmacol"},{"key":"2065_CR13","doi-asserted-by":"publisher","first-page":"e1262","DOI":"10.1212\/wnl.0000000000200048","volume":"98","author":"M van de Beek","year":"2022","unstructured":"van de Beek M, et al. Association of the ATN Research Framework With Clinical Profile, Cognitive Decline, and Mortality in Patients With Dementia With Lewy Bodies. Neurology. 2022;98:e1262\u201372. https:\/\/doi.org\/10.1212\/wnl.0000000000200048.","journal-title":"Neurology"},{"key":"2065_CR14","doi-asserted-by":"publisher","unstructured":"Beach TG et al. Clinicopathological Heterogeneity of Lewy Body Diseases: The Profound Influence of Comorbid Alzheimer\u2019s Disease. medRxiv (2024). https:\/\/doi.org\/10.1101\/2024.08.30.24312864","DOI":"10.1101\/2024.08.30.24312864"},{"key":"2065_CR15","doi-asserted-by":"publisher","unstructured":"IrizarryM et al. Results of a Phase 2\/3 Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Study to Evaluate the Efficacy and Safety of 12 Week Treatment with the Phosphodiesterase 9 (PDE9) Inhibitor Irsenontrine (E2027) in Subjects With Dementia With Lewy BodiesClinical Trials on Alzheimer\u2019s disease (2022).15th Conference Clinical Trials Alzheimer\u2019s Disease, November 29\u2013December 2, 2022, San Francisco, CA, USA: Posters (Clinical Trial Alzheimer\u2019s Disease). J Prev Alzheimers Dis. 2022;9(Suppl 1):51\u2013248. https:\/\/doi.org\/10.14283\/jpad.2022.97.","DOI":"10.14283\/jpad.2022.97"},{"key":"2065_CR16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s13311-014-0327-5","volume":"12","author":"AF Teich","year":"2015","unstructured":"Teich AF, et al. Synaptic Therapy in Alzheimer\u2019s Disease: A CREB-centric Approach. Neurotherapeutics. 2015;12:29\u201341. https:\/\/doi.org\/10.1007\/s13311-014-0327-5.","journal-title":"Neurotherapeutics"},{"key":"2065_CR17","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1002\/alz.12897","volume":"19","author":"A Leuzy","year":"2023","unstructured":"Leuzy A, et al. Robustness of CSF A\u03b242\/40 and A\u03b242\/P-tau181 measured using fully automated immunoassays to detect AD-related outcomes. Alzheimer\u2019s Dement. 2023;19:2994\u20133004. https:\/\/doi.org\/10.1002\/alz.12897.","journal-title":"Alzheimer\u2019s Dement"},{"key":"2065_CR18","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13195-015-0114-5","volume":"7","author":"J Dumurgier","year":"2015","unstructured":"Dumurgier J, et al. Cerebrospinal fluid amyloid-\u03b2 42\/40 ratio in clinical setting of memory centers: a multicentric study. Alzheimers Res Ther. 2015;7:30. https:\/\/doi.org\/10.1186\/s13195-015-0114-5.","journal-title":"Alzheimers Res Ther"},{"key":"2065_CR19","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3233\/jad-132306","volume":"41","author":"WM van der Flier","year":"2014","unstructured":"van der Flier WM, et al. Optimizing patient care and research: the Amsterdam Dementia Cohort. J Alzheimers Dis. 2014;41:313\u201327. https:\/\/doi.org\/10.3233\/jad-132306.","journal-title":"J Alzheimers Dis"},{"key":"2065_CR20","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3233\/JAD-170850","volume":"62","author":"WM van der Flier","year":"2018","unstructured":"van der Flier WM, Scheltens P. Amsterdam Dementia Cohort: Performing Research to Optimize Care. J Alzheimers Dis. 2018;62:1091\u2013111. https:\/\/doi.org\/10.3233\/JAD-170850.","journal-title":"J Alzheimers Dis"},{"key":"2065_CR21","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.jalz.2013.12.023","volume":"10","author":"FH Duits","year":"2014","unstructured":"Duits FH, et al. The cerebrospinal fluid Alzheimer profile: Easily said, but what does it mean? Alzheimer\u2019s Dement. 2014;10:713\u2013e723712. https:\/\/doi.org\/10.1016\/j.jalz.2013.12.023.","journal-title":"Alzheimer\u2019s Dement"},{"key":"2065_CR22","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1373\/clinchem.2017.281055","volume":"64","author":"BM Tijms","year":"2018","unstructured":"Tijms BM, et al. Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid-\u03b2 1\u201342 Analysis Results. Clin Chem. 2018;64:576\u201385. https:\/\/doi.org\/10.1373\/clinchem.2017.281055.","journal-title":"Clin Chem"},{"key":"2065_CR23","doi-asserted-by":"publisher","first-page":"4495","DOI":"10.1093\/brain\/awad213","volume":"146","author":"EL van der Ende","year":"2023","unstructured":"van der Ende EL, et al. CSF proteomics in autosomal dominant Alzheimer\u2019s disease highlights parallels with sporadic disease. Brain. 2023;146:4495\u2013507. https:\/\/doi.org\/10.1093\/brain\/awad213.","journal-title":"Brain"},{"key":"2065_CR24","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1038\/s43587-022-00300-1","volume":"2","author":"M del Campo","year":"2022","unstructured":"del Campo M, et al. CSF proteome profiling across the Alzheimer\u2019s disease spectrum reflects the multifactorial nature of the disease and identifies specific biomarker panels. Nat Aging. 2022;2:1040\u201353. https:\/\/doi.org\/10.1038\/s43587-022-00300-1.","journal-title":"Nat Aging"},{"key":"2065_CR25","doi-asserted-by":"publisher","first-page":"5635","DOI":"10.1038\/s41467-023-41122-y","volume":"14","author":"M del Campo","year":"2023","unstructured":"del Campo M, et al. CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer\u00b4s disease. Nat Commun. 2023;14:5635. https:\/\/doi.org\/10.1038\/s41467-023-41122-y.","journal-title":"Nat Commun"},{"key":"2065_CR26","doi-asserted-by":"publisher","unstructured":"Hok-A-Hin YS et al. Large-scale CSF proteome profiling identifies biomarkers for accurate diagnosis of Frontotemporal Dementia. medRxiv, 2024.2008.2019.24312100 (2024). https:\/\/doi.org\/10.1101\/2024.08.19.24312100","DOI":"10.1101\/2024.08.19.24312100"},{"key":"2065_CR27","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.7150\/jca.15486","volume":"7","author":"S Wanggou","year":"2016","unstructured":"Wanggou S, et al. Sample Level Enrichment Analysis of KEGG Pathways Identifies Clinically Relevant Subtypes of Glioblastoma. J Cancer. 2016;7:1701\u201310. https:\/\/doi.org\/10.7150\/jca.15486.","journal-title":"J Cancer"},{"key":"2065_CR28","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28:27\u201330. https:\/\/doi.org\/10.1093\/nar\/28.1.27.","journal-title":"Nucleic Acids Res"},{"key":"2065_CR29","doi-asserted-by":"publisher","unstructured":"Sachdev P, et al. The effects of the novel phosphodiesterase 9 (pde9) inhibitor e2027 (irsenontrine) on csf cgmp, additional csf and plasma biomarkers, and clinical outcomes in amyloid positive and amyloid negative patients with dementia with lewy bodies (dlb) and parkinson\u2019s disease dementia (pdd). 15th Conference Clinical Trials Alzheimer\u2019s Disease, November 29\u2013December 2, 2022, San Francisco, CA, USA: Posters (Clinical Trial Alzheimer\u2019s Disease). J Prev Alzheimers Dis. 2022;9(Suppl 1):51\u2013248. https:\/\/doi.org\/10.14283\/jpad.2022.97.","DOI":"10.14283\/jpad.2022.97"},{"key":"2065_CR30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40035-024-00421-0","volume":"13","author":"E Appleton","year":"2024","unstructured":"Appleton E, et al. DOPA-decarboxylase is elevated in CSF, but not plasma, in prodromal and de novo Parkinson\u2019s disease. Transl Neurodegener. 2024;13:31. https:\/\/doi.org\/10.1186\/s40035-024-00421-0.","journal-title":"Transl Neurodegener"},{"key":"2065_CR31","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40035-023-00374-w","volume":"12","author":"W Paslawski","year":"2023","unstructured":"Paslawski W, et al. Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson\u2019s disease. Transl Neurodegener. 2023;12:42. https:\/\/doi.org\/10.1186\/s40035-023-00374-w.","journal-title":"Transl Neurodegener"},{"key":"2065_CR32","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1038\/s43587-023-00478-y","volume":"3","author":"JB Pereira","year":"2023","unstructured":"Pereira JB, et al. DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease. Nat Aging. 2023;3:1201\u20139. https:\/\/doi.org\/10.1038\/s43587-023-00478-y.","journal-title":"Nat Aging"},{"key":"2065_CR33","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s00401-024-02706-0","volume":"147","author":"J Rutledge","year":"2024","unstructured":"Rutledge J, et al. Comprehensive proteomics of CSF, plasma, and urine identify DDC and other biomarkers of early Parkinson\u2019s disease. Acta Neuropathol. 2024;147:52. https:\/\/doi.org\/10.1007\/s00401-024-02706-0.","journal-title":"Acta Neuropathol"},{"key":"2065_CR34","doi-asserted-by":"publisher","unstructured":"Higginbotham L et al. Multiplex Proteomics of Lewy Body Dementia Reveals Cerebrospinal Fluid Biomarkers of Disease Pathology and Progression. bioRxiv, 2025.2006.2010.658994 (2025). https:\/\/doi.org\/10.1101\/2025.06.10.658994","DOI":"10.1101\/2025.06.10.658994"},{"key":"2065_CR35","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.bbrc.2019.11.052","volume":"522","author":"N Ismail","year":"2020","unstructured":"Ismail N, et al. Vitamin B5 (d-pantothenic acid) localizes in myelinated structures of the rat brain: Potential role for cerebral vitamin B5 stores in local myelin homeostasis. Biochem Biophys Res Commun. 2020;522:220\u20135. https:\/\/doi.org\/10.1016\/j.bbrc.2019.11.052.","journal-title":"Biochem Biophys Res Commun"},{"key":"2065_CR36","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/S0006-2952(02)01623-4","volume":"65","author":"J Garc\u0131\u0301a-Villafranca","year":"2003","unstructured":"Garc\u0131\u0301a-Villafranca J, Guill\u00e9n A, Castro J. Involvement of nitric oxide\/cyclic GMP signaling pathway in the regulation of fatty acid metabolism in rat hepatocytes. Biochem Pharmacol. 2003;65:807\u201312. https:\/\/doi.org\/10.1016\/S0006-2952(02)01623-4.","journal-title":"Biochem Pharmacol"},{"key":"2065_CR37","doi-asserted-by":"publisher","unstructured":"Scholefield M, et al. Substantively Lowered Levels of Pantothenic Acid (Vitamin B5) in Several Regions of the Human Brain in Parkinson\u2019s Disease Dementia. Metabolites. 2021;11. https:\/\/doi.org\/10.3390\/metabo11090569.","DOI":"10.3390\/metabo11090569"},{"key":"2065_CR38","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.bbrc.2020.05.015","volume":"527","author":"J Xu","year":"2020","unstructured":"Xu J, et al. Cerebral deficiency of vitamin B5 (d-pantothenic acid; pantothenate) as a potentially-reversible cause of neurodegeneration and dementia in sporadic Alzheimer\u2019s disease. Biochem Biophys Res Commun. 2020;527:676\u201381. https:\/\/doi.org\/10.1016\/j.bbrc.2020.05.015.","journal-title":"Biochem Biophys Res Commun"},{"key":"2065_CR39","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jagp.2019.06.007","volume":"28","author":"AP Rajkumar","year":"2020","unstructured":"Rajkumar AP, et al. Postmortem Cortical Transcriptomics of Lewy Body Dementia Reveal Mitochondrial Dysfunction and Lack of Neuroinflammation. Am J Geriatric Psychiatry. 2020;28:75\u201386. https:\/\/doi.org\/10.1016\/j.jagp.2019.06.007.","journal-title":"Am J Geriatric Psychiatry"},{"key":"2065_CR40","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1093\/brain\/awae069","volume":"147","author":"N Okkels","year":"2024","unstructured":"Okkels N, et al. Cholinergic changes in Lewy body disease: implications for presentation, progression and subtypes. Brain. 2024;147:2308\u201324. https:\/\/doi.org\/10.1093\/brain\/awae069.","journal-title":"Brain"},{"key":"2065_CR41","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41580-022-00490-x","volume":"23","author":"Y Posor","year":"2022","unstructured":"Posor Y, Jang W, Haucke V. Phosphoinositides as membrane organizers. Nat Rev Mol Cell Biol. 2022;23:797\u2013816. https:\/\/doi.org\/10.1038\/s41580-022-00490-x.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2065_CR42","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/978-94-007-3015-1_5","volume":"59","author":"SG Frere","year":"2012","unstructured":"Frere SG, Chang-Ileto B, Di Paolo G. Role of phosphoinositides at the neuronal synapse. Subcell Biochem. 2012;59:131\u201375. https:\/\/doi.org\/10.1007\/978-94-007-3015-1_5.","journal-title":"Subcell Biochem"},{"key":"2065_CR43","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1159\/000065431","volume":"11","author":"RR Fiscus","year":"2002","unstructured":"Fiscus RR. Involvement of Cyclic GMP and Protein Kinase G in the Regulation of Apoptosis and Survival in Neural Cells. Neurosignals. 2002;11:175\u201390. https:\/\/doi.org\/10.1159\/000065431.","journal-title":"Neurosignals"},{"key":"2065_CR44","doi-asserted-by":"publisher","first-page":"48093","DOI":"10.1074\/jbc.M108622200","volume":"276","author":"K Takuma","year":"2001","unstructured":"Takuma K, et al. Anti-apoptotic Effect of cGMP in Cultured Astrocytes: INHIBITION BY cGMP-DEPENDENT PROTEIN KINASE OF MITOCHONDRIAL PERMEABLE TRANSITION PORE*. J Biol Chem. 2001;276:48093\u20139. https:\/\/doi.org\/10.1074\/jbc.M108622200.","journal-title":"J Biol Chem"},{"key":"2065_CR45","doi-asserted-by":"publisher","first-page":"102123","DOI":"10.1016\/j.arr.2023.102123","volume":"92","author":"J Rivera","year":"2023","unstructured":"Rivera J, Sharma B, Torres MM, Kumar S. Factors affecting the GABAergic synapse function in Alzheimer\u2019s disease: Focus on microRNAs. Ageing Res Rev. 2023;92:102123. https:\/\/doi.org\/10.1016\/j.arr.2023.102123.","journal-title":"Ageing Res Rev"},{"key":"2065_CR46","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.tins.2024.11.007","volume":"48","author":"D Krueger-Burg","year":"2025","unstructured":"Krueger-Burg D. Understanding GABAergic synapse diversity and its implications for GABAergic pharmacotherapy. Trends Neurosci. 2025;48:47\u201361. https:\/\/doi.org\/10.1016\/j.tins.2024.11.007.","journal-title":"Trends Neurosci"},{"key":"2065_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neubiorev.2016.01.007","volume":"63","author":"CF Heaney","year":"2016","unstructured":"Heaney CF, Kinney JW. Role of GABAB receptors in learning and memory and neurological disorders. Neurosci Biobehavioral Reviews. 2016;63:1\u201328. https:\/\/doi.org\/10.1016\/j.neubiorev.2016.01.007.","journal-title":"Neurosci Biobehavioral Reviews"},{"key":"2065_CR48","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1242\/dev.102608","volume":"141","author":"C Giachino","year":"2014","unstructured":"Giachino C, et al. GABA suppresses neurogenesis in the adult hippocampus through GABAB receptors. Development. 2014;141:83\u201390. https:\/\/doi.org\/10.1242\/dev.102608.","journal-title":"Development"},{"key":"2065_CR49","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.neuint.2004.03.018","volume":"45","author":"CJ Barnstable","year":"2004","unstructured":"Barnstable CJ, Wei J-Y, Han M-H. Modulation of synaptic function by cGMP and cGMP-gated cation channels. Neurochem Int. 2004;45:875\u201384. https:\/\/doi.org\/10.1016\/j.neuint.2004.03.018.","journal-title":"Neurochem Int"},{"key":"2065_CR50","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1523\/jneurosci.18-07-02342.1998","volume":"18","author":"EM Wexler","year":"1998","unstructured":"Wexler EM, Stanton PK, Nawy S. Nitric Oxide Depresses GABA\u2009<\u2009sub>A Receptor Function via Coactivation of cGMP-Dependent Kinase and Phosphodiesterase. J Neurosci. 1998;18:2342\u20139. https:\/\/doi.org\/10.1523\/jneurosci.18-07-02342.1998.","journal-title":"J Neurosci"},{"key":"2065_CR51","doi-asserted-by":"publisher","first-page":"5025","DOI":"10.1038\/s41380-023-02140-w","volume":"28","author":"G Carello-Collar","year":"2023","unstructured":"Carello-Collar G, et al. The GABAergic system in Alzheimer\u2019s disease: a systematic review with meta-analysis. Mol Psychiatry. 2023;28:5025\u201336. https:\/\/doi.org\/10.1038\/s41380-023-02140-w.","journal-title":"Mol Psychiatry"},{"key":"2065_CR52","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1002\/alz.12088","volume":"16","author":"D Bi","year":"2020","unstructured":"Bi D, Wen L, Wu Z, Shen Y. GABAergic dysfunction in excitatory and inhibitory (E\/I) imbalance drives the pathogenesis of Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2020;16:1312\u201329. https:\/\/doi.org\/10.1002\/alz.12088.","journal-title":"Alzheimer\u2019s Dement"},{"key":"2065_CR53","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/s41392-023-01503-7","volume":"8","author":"S Wang","year":"2023","unstructured":"Wang S, et al. The mitophagy pathway and its implications in human diseases. Signal Transduct Target Therapy. 2023;8:304. https:\/\/doi.org\/10.1038\/s41392-023-01503-7.","journal-title":"Signal Transduct Target Therapy"},{"key":"2065_CR54","doi-asserted-by":"publisher","unstructured":"Scott GD et al. Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium. Front Neurol 12, 805135 (2021). https:\/\/doi.org\/10.3389\/fneur.2021.805135","DOI":"10.3389\/fneur.2021.805135"},{"key":"2065_CR55","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1097\/wco.0000000000001173","volume":"36","author":"LL Gibson","year":"2023","unstructured":"Gibson LL, Abdelnour C, Chong J, Ballard C, Aarsland D. Clinical trials in dementia with Lewy bodies: the evolving concept of co-pathologies, patient selection and biomarkers. Curr Opin Neurol. 2023;36:264\u201375. https:\/\/doi.org\/10.1097\/wco.0000000000001173.","journal-title":"Curr Opin Neurol"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-026-02065-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-02065-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-02065-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:45:53Z","timestamp":1780879553000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13195-026-02065-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2065"],"URL":"https:\/\/doi.org\/10.1186\/s13195-026-02065-w","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"5 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial was conducted in accordance with ICH guidelines and the ethical principles of the Declaration of Helsinki. The trial was approved by an independent local ethical committee at each participating country\/center. Ethical approval of the sub-study was provided by a local review board of the Amsterdam UMC. All study participants or a representative provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"139"}}